Ayala Pharmaceuticals Performance
| ADXSDelisted Stock | USD 1.38 0.34 32.69% |
The firm shows a Beta (market volatility) of -1.64, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Ayala Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Ayala Pharmaceuticals is expected to outperform it. Ayala Pharmaceuticals right now shows a risk of 0.0%. Please confirm Ayala Pharmaceuticals kurtosis, market facilitation index, as well as the relationship between the value at risk and standard deviation , to decide if Ayala Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Ayala Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Ayala Pharmaceuticals is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Quick Ratio | 14.77 | |
| Fifty Two Week Low | 1.5600 | |
| Fifty Two Week High | 33.6000 |
Ayala |
Ayala Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 138.00 in Ayala Pharmaceuticals on August 26, 2024 and sell it today you would earn a total of 0.00 from holding Ayala Pharmaceuticals or generate 0.0% return on investment over 90 days. Ayala Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of otc stocks are less volatile than Ayala, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ayala Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ayala Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Ayala Pharmaceuticals, and traders can use it to determine the average amount a Ayala Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ADXS |
Based on monthly moving average Ayala Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ayala Pharmaceuticals by adding Ayala Pharmaceuticals to a well-diversified portfolio.
Ayala Pharmaceuticals Fundamentals Growth
Ayala OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Ayala Pharmaceuticals, and Ayala Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ayala OTC Stock performance.
| Return On Equity | -41.98 | ||||
| Return On Asset | -24.13 | ||||
| Current Valuation | (25.1 M) | ||||
| Shares Outstanding | 145.64 M | ||||
| Price To Earning | (1.62) X | ||||
| Price To Book | 5.25 X | ||||
| Price To Sales | 990.34 X | ||||
| Revenue | 250 K | ||||
| EBITDA | (15.31 M) | ||||
| Cash And Equivalents | 28.15 M | ||||
| Cash Per Share | 15.50 X | ||||
| Total Debt | 19 K | ||||
| Book Value Per Share | 0.32 X | ||||
| Cash Flow From Operations | (16.04 M) | ||||
| Earnings Per Share | (0.33) X | ||||
| Total Asset | 169.04 M | ||||
| Retained Earnings | (354.94 M) | ||||
| Current Asset | 159.88 M | ||||
| Current Liabilities | 27.71 M |
About Ayala Pharmaceuticals Performance
Assessing Ayala Pharmaceuticals' fundamental ratios provides investors with valuable insights into Ayala Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Ayala Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes technology antigen delivery products in the United States. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey. Advaxis operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 14 people.Things to note about Ayala Pharmaceuticals performance evaluation
Checking the ongoing alerts about Ayala Pharmaceuticals for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Ayala Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ayala Pharmaceuticals is not yet fully synchronised with the market data | |
| Ayala Pharmaceuticals may become a speculative penny stock | |
| Ayala Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 250 K. Net Loss for the year was (16.24 M) with profit before overhead, payroll, taxes, and interest of 3.24 M. | |
| Ayala Pharmaceuticals currently holds about 28.15 M in cash with (16.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.5, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Ayala Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ayala Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Ayala Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ayala Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ayala Pharmaceuticals' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Ayala Pharmaceuticals' otc stock. These opinions can provide insight into Ayala Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Ayala OTC Stock
If you are still planning to invest in Ayala Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ayala Pharmaceuticals' history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |